Literature DB >> 19011565

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

Michael H Roh1, David Kindelberger, Christopher P Crum.   

Abstract

Pelvic serous cancer is a diverse disease, and the assignment of primary site -- ovarian, tubal, or peritoneal -- is often problematic. Recent studies indicate that a proportion of these tumors arise from the distal fallopian tube, originating as serous tubal intraepithelial carcinoma (STIC). This study examined the relationship of 2 parameters for assigning origin -- endosalpingeal involvement and dominant ovarian mass -- in the context of STIC. Endometrioid carcinomas served as a reference. Eighty-seven consecutive pelvic serous cancers in which the tubes and ovaries were completely examined (SEE-FIM protocol) were analyzed. The presence of a dominant ovarian mass (DOM+), involvement of the fimbrial mucosa (FIM+), and STIC were correlated. In addition, tumor categories were compared with respect to PAX8, p73, p53, and p16 immunohistochemistry. Of the 27 DOM+ cases, 13 (48%) were FIM+ and a STIC was present in 3 (11%). Of the 60 DOM(-) cases, 48 (78%) were FIM+ and 28 (45%) harbored a STIC. In 92% of all cases, tumor distribution was extensive with bilateral ovarian and extraovarian peritoneal involvement. All tumor categories were immunophenotypically similar. In contrast, DOM+, FIM+, and STIC were found in 81%, 19%, and 0% of ovarian endometrioid carcinomas. In conclusion, there is a significant inverse relationship between DOM+ and STIC (P=0.001), indicating both parameters are of value in grouping pelvic serous carcinomas more likely to be ovarian [DOM+/FIM(-)] versus fimbrial [DOM(-)/STIC], and ovarian or peritoneal surface (DOM-/FIM-) in origin. Nevertheless, the shared immunophenotype suggests a common cell of origin for all categories, irrespective of site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19011565     DOI: 10.1097/PAS.0b013e3181868904

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  45 in total

1.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

2.  Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Authors:  Mika Fujiwara; Valerie A McGuire; Anna Felberg; Weiva Sieh; Alice S Whittemore; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

Review 3.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

Review 4.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 5.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

6.  Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Marc T Goodman; Valerie McGuire; Mary Anne Rossing; Penelope M Webb; Martin Köbel; Hoda Anton-Culver; Jonathan Beesley; Andrew Berchuck; Sony Brar; Michael E Carney; Jenny Chang-Claude; Georgia Chenevix-Trench; Daniel W Cramer; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Zachary S Fredericksen; Brooke L Fridley; Margaret A Gates; Simon A Gayther; Aleksandra Gentry-Maharaj; Estrid Høgdall; Susanne Krüger Kjaer; Galina Lurie; Usha Menon; Patricia G Moorman; Kirsten Moysich; Roberta B Ness; Rachel T Palmieri; Celeste L Pearce; Paul D P Pharoah; Susan J Ramus; Honglin Song; Daniel O Stram; Shelley S Tworoger; David Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Alice S Whittemore; Lynne R Wilkens; Anna H Wu; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

7.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

8.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

9.  Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Authors:  Katherine V Clark-Knowles; Mary K Senterman; Olga Collins; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.